Vellum Biosciences

Vellum Biosciences is a biotechnology company focused on developing first-in-class therapies for neurodegenerative diseases by targeting reactive astrocytes. The company's platform is built on the discovery of neurotoxic astrocyte states that drive neuronal loss in conditions like Alzheimer's, ALS, and Parkinson's. By modulating these specific cellular pathways, Vellum aims to halt disease progression rather than merely managing symptoms. Headquartered in New York, the company leverages cutting-edge neurobiology to advance its pipeline of pre-clinical candidates toward the clinic. The company was founded based on research from NYU Langone Health and is supported by prominent venture capital firms.